Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > We are still in the pre-clinical stage.
View:
Post by Rarbar99 on Oct 04, 2021 10:50am

We are still in the pre-clinical stage.

The FDA processing is far more rigorous and strict than it is here in Canada. In the eyes of the FDA, we are still in the pre-clinical stage. Not even stage 1. 


it's important for everyone to know this.

Comment by MrMugsy on Oct 04, 2021 11:52am
I don't think it's that simple. With all the data that's been collected - and all the data that is being collected - the FDA will be clear about what they still want to see. It all depends on what ATE finds and the direction(s) they'd like to pursue. Likely - a smaller P2 will be required before a P3 in one aspect. But, I also see an opportunity for a P2/3 in a different aspect ...more  
Comment by themagicbox on Oct 04, 2021 1:08pm
Hes on ignore but I got to see his comment through your reply. Funny how he says that without a shred of evidence. Any FDA stage classfication document to back this nonsense comment?
Comment by Candyswanwick on Oct 04, 2021 12:09pm
Otenaproxesul isn't considered a preclinical drug. Lol. 
Comment by Rarbar99 on Oct 04, 2021 1:16pm
  Tell that to Antibe. They released this report back in March 2021: https://antibethera.com/news/antibe-therapeutics-receives-fda-clearance-of-ind-application-for-otenaproxesul-for-osteoarthritis/ The FDA does not care what-so-ever about Health Canada. If Antibe wants FDA approval, it needs to go through Ph1, Ph2, Ph3 and NDA all over again. Right now they're at the very ...more  
Comment by StockingUp21 on Oct 04, 2021 1:46pm
CAN WE GET MUGGY OR ANOTHER EMPLOYEE TO CLAREIFY
Comment by Candyswanwick on Oct 04, 2021 2:28pm
Dude did you even read the article you posted? I'm concerned that you don't know how to read.
Comment by Candyswanwick on Oct 04, 2021 2:39pm
I'll try to be patient... "Antibe is a clinical stage drug company" is literally the first sentence. They then go on to say they have given clinical data to the FDA. If Otena is a preclinical drug, where did they get their clinical data to give the FDA? Do you know what clinical means? 
Comment by Inthepez on Oct 04, 2021 4:30pm
Lmao!!
Comment by muto412 on Oct 04, 2021 11:58pm
Otena is not a pre-clinical drug. A pre-clinical drug has never been tested in humans. We have dosing down to 75mg in humans which showed cox inhibition. This phase 1 trial showed it was safe up to 250mg/day for 14 days.  Please read about clinical trials.  https://antibethera.com/news/antibe-announces-completion-of-phase-i-studies-of-atb-346-and-an-update-on-its-validation-studies/
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities